Tikun Olam-Cannbit Pharmaceuticals Full Year 2023 Earnings: ₪1.41 loss per share (vs ₪0.99 loss in FY 2022)

Simply Wall St

April 03, 2024

Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Full Year 2023 Results

Key Financial Results

Revenue: ₪44.2m (down 10% from FY 2022).
Net loss: ₪88.9m (loss widened by 84% from FY 2022).
₪1.41 loss per share (further deteriorated from ₪0.99 loss in FY 2022).

earnings-and-revenue-history — TASE:TKUN Earnings and Revenue History April 3rd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Tikun Olam-Cannbit Pharmaceuticals shares are down 3.0% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 5 warning signs for Tikun Olam-Cannbit Pharmaceuticals (4 are significant!) that you should be aware of.

If you're looking to trade Tikun Olam-Cannbit Pharmaceuticals, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if Tikun Olam-Cannbit Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.